LCO No. 826 1 of 1
General Assembly Proposed Bill No. 641
January Session, 2021
LCO No. 826
Referred to Committee on GENERAL LAW
Introduced by:
SEN. LOONEY, 11
th Dist.
AN ACT REQUIRING MANUFACTURERS OF BRAND -NAME
PRESCRIPTION DRUGS TO PROVIDE SAMPLES OF SUCH DRUGS
TO MANUFACTURERS OF GENERIC PRESCRIPTION DRUGS.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:
That the general statutes be amended to require brand-name 1
prescription drug manufacturers to sell sufficient samples to generic 2
drug manufacturers. 3
Statement of Purpose:
To promote competition in the prescription drug market by allowing
developers of generic drugs and biosimilar products to obtain reference
samples.